Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia
Author:
Affiliation:
1. 1IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli,” Bologna, Italy
2. 2Dipartimento di Scienze Mediche e Chirurgiche, Università di Bologna, Bologna, Italy
Publisher
American Society of Hematology
Subject
Hematology
Link
https://ashpublications.org/bloodadvances/article-pdf/7/21/6762/2089015/blooda_adv-2023-010742-main.pdf
Reference24 articles.
1. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis;Else;Br J Haematol,2009
2. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia;Cornet;Br J Haematol,2014
3. Is it really possible to cure hairy cell leukemia patients only with frontline therapy?;Zinzani;Ann Hematol,2014
4. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: a 30-year experience;Broccoli;Am J Hematol,2021
5. A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia;Broccoli;Blood Adv,2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3